Literature DB >> 8246705

Markov models in medical decision making: a practical guide.

F A Sonnenberg1, J R Beck.   

Abstract

Markov models are useful when a decision problem involves risk that is continuous over time, when the timing of events is important, and when important events may happen more than once. Representing such clinical settings with conventional decision trees is difficult and may require unrealistic simplifying assumptions. Markov models assume that a patient is always in one of a finite number of discrete health states, called Markov states. All events are represented as transitions from one state to another. A Markov model may be evaluated by matrix algebra, as a cohort simulation, or as a Monte Carlo simulation. A newer representation of Markov models, the Markov-cycle tree, uses a tree representation of clinical events and may be evaluated either as a cohort simulation or as a Monte Carlo simulation. The ability of the Markov model to represent repetitive events and the time dependence of both probabilities and utilities allows for more accurate representation of clinical settings that involve these issues.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8246705     DOI: 10.1177/0272989X9301300409

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  501 in total

1.  Costs of Mini Mental State Examination-related cognitive impairment.

Authors:  L Jönsson; P Lindgren; A Wimo; B Jönsson; B Winblad
Journal:  Pharmacoeconomics       Date:  1999-10       Impact factor: 4.981

2.  Development of the health and economic consequences of smoking interactive model.

Authors:  M E Orme; S L Hogue; L M Kennedy; A C Paine; C Godfrey
Journal:  Tob Control       Date:  2001-03       Impact factor: 7.552

Review 3.  Selecting a decision model for economic evaluation: a case study and review.

Authors:  J Karnon; J Brown
Journal:  Health Care Manag Sci       Date:  1998-10

Review 4.  Assessing quality in decision analytic cost-effectiveness models. A suggested framework and example of application.

Authors:  M Sculpher; E Fenwick; K Claxton
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

Review 5.  Handling uncertainty in cost-effectiveness models.

Authors:  A H Briggs
Journal:  Pharmacoeconomics       Date:  2000-05       Impact factor: 4.981

Review 6.  An introduction to Markov modelling for economic evaluation.

Authors:  A Briggs; M Sculpher
Journal:  Pharmacoeconomics       Date:  1998-04       Impact factor: 4.981

Review 7.  Selective COX-2 inhibitors: a health economic perspective.

Authors:  David L B Schwappach; Christian M Koeck
Journal:  Wien Med Wochenschr       Date:  2003

8.  Dyspepsia management in the millennium: to test and treat or not?

Authors:  B C Delaney
Journal:  Gut       Date:  2003-01       Impact factor: 23.059

9.  Economic value of using partially hydrolysed infant formula for risk reduction of atopic dermatitis in high-risk, not exclusively breastfed infants in Singapore.

Authors:  Marc F Botteman; Abhijeet J Bhanegaonkar; Erica G Horodniceanu; Xiang Ji; Bee Wah Lee; Lynette P Shek; Hugo Ps Van Bever; Patrick Detzel
Journal:  Singapore Med J       Date:  2017-12-07       Impact factor: 1.858

10.  The costs and benefits of automatic estimated glomerular filtration rate reporting.

Authors:  Julia R den Hartog; Peter P Reese; Borut Cizman; Harold I Feldman
Journal:  Clin J Am Soc Nephrol       Date:  2009-01-28       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.